Binduravikumar (talk | contribs) |
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot |
||
Line 1: | Line 1: | ||
{{ |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
| Watchedfields = changed |
||
| verifiedrevid = 436591036 |
| verifiedrevid = 436591036 |
||
| IUPAC_name = (11β,16α)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate |
| IUPAC_name = (11β,16α)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate |
||
⚫ | |||
| image2 = Mometasone furoate.png |
| image2 = Mometasone furoate.png |
||
⚫ | |||
<!--Clinical data--> |
|||
⚫ | |||
| tradename = |
|||
⚫ | |||
| Drugs.com = {{drugs.com|monograph|mometasone_furoate}} |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Pharmacokinetic data--> |
|||
⚫ | | bioavailability = Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to [[fluticasone]].<ref>{{cite journal | title = Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate | author = Zia R Tayab, Tom C Fardon, Daniel K C Lee, Kay Haggart, Lesley C McFarlane, Brian J Lipworth, and Günther Hochhaus | journal = Br J Clin Pharmacol | year = 2007 | month = November | volume = 64 | issue = 5 | pages = 698–705 | doi = 10.1111/j.1365-2125.2007.02919.x | pmid = 17509041 | pmc = 2203259}}</ref> |
||
⚫ | |||
⚫ | |||
⚫ | |||
<!--Identifiers--> |
|||
| CAS_number = 105102-22-5 |
| CAS_number = 105102-22-5 |
||
| CAS_supplemental = {{CAS|83919-23-7}} |
| CAS_supplemental = {{CAS|83919-23-7}} |
||
| ATC_prefix = D07 |
| ATC_prefix = D07 |
||
| ATC_suffix = AC13 |
| ATC_suffix = AC13 |
||
| ATC_supplemental = {{ATC|D07|XC03}}, {{ATC|R01|AD09}}, {{ATC|R03|BA07}} |
| ATC_supplemental = {{ATC|D07|XC03}}, {{ATC|R01|AD09}}, {{ATC|R03|BA07}} |
||
⚫ | |||
⚫ | |||
| PubChem = 441336 |
| PubChem = 441336 |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = APRD00289 |
| DrugBank = APRD00289 |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
||
| ChEMBL = 1161 |
| ChEMBL = 1161 |
||
<!--Chemical data--> |
|||
| chemical_formula = C<sub>22</sub>H<sub>28</sub>Cl<sub>2</sub>O<sub>4</sub> for Mometasone<br> C<sub>27</sub>H<sub>30</sub>O<sub>6</sub>Cl<sub>2</sub> as Furoate |
| chemical_formula = C<sub>22</sub>H<sub>28</sub>Cl<sub>2</sub>O<sub>4</sub> for Mometasone<br> C<sub>27</sub>H<sub>30</sub>O<sub>6</sub>Cl<sub>2</sub> as Furoate |
||
| molecular_weight = 427.361 g/mol (Mometasone) <br> 521.4 g/mol (Furoate) |
| molecular_weight = 427.361 g/mol (Mometasone) <br> 521.4 g/mol (Furoate) |
||
| smiles = O=C(O[C@]2(C(=O)CCl)[C@H](C)C[C@H]3[C@@H]4CCC\1=C\C(=O)\C=C/[C@]/1(C)[C@@]4(Cl)[C@@H](O)C[C@]23C)c5occc5 |
| smiles = O=C(O[C@]2(C(=O)CCl)[C@H](C)C[C@H]3[C@@H]4CCC\1=C\C(=O)\C=C/[C@]/1(C)[C@@]4(Cl)[C@@H](O)C[C@]23C)c5occc5 |
||
⚫ | |||
⚫ | | bioavailability = Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to [[fluticasone]].<ref>{{cite journal|title=Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate|author=Zia R Tayab, Tom C Fardon, Daniel K C Lee, Kay Haggart, Lesley C McFarlane, Brian J Lipworth, and Günther Hochhaus|journal=Br J Clin Pharmacol|year=2007|month=November|volume=64|issue=5|pages=698–705|doi=10.1111/j.1365-2125.2007.02919.x|pmid=17509041|pmc=2203259}}</ref> |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| pregnancy_category = |
|||
⚫ | |||
⚫ | |||
⚫ | |||
}} |
}} |
||
'''Mometasone furoate''' (also referred to as '''mometasone''') is a [[glucocorticoid]] [[steroid]] used topically to reduce [[inflammation]] of the [[skin]] or in the [[airway]]s. |
'''Mometasone furoate''' (also referred to as '''mometasone''') is a [[glucocorticoid]] [[steroid]] used topically to reduce [[inflammation]] of the [[skin]] or in the [[airway]]s. |
Revision as of 23:21, 30 August 2011
Clinical data | |
---|---|
Other names | (9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate |
AHFS/Drugs.com | Monograph |
Routes of administration | topical, nasal |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | Nasal spray is virtually undetectable in plasma; but systemic availability is comparable to fluticasone.[1] |
Protein binding | 98% to 99% |
Metabolism | hepatic |
Elimination half-life | 5.8 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.125.600 |
Chemical and physical data | |
Formula | C22H28Cl2O4 for Mometasone C27H30O6Cl2 as Furoate |
Molar mass | 427.361 g/mol (Mometasone) 521.4 g/mol (Furoate) |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Mometasone furoate (also referred to as mometasone) is a glucocorticoid steroid used topically to reduce inflammation of the skin or in the airways.
Uses, administration, and pharmacodynamics
Mometasone furoate is used in the treatment of inflammatory skin disorders (such as eczema and psoriasis), allergic rhinitis (such as hay fever), asthma[2][3] for patients unresponsive to less potent corticosteroids, and penile phimosis.[4] In terms of steroid strength, it is more potent than hydrocortisone, and less potent than dexamethasone.[citation needed]
It reduces inflammation by causing several effects:[5][6]
- reversing the activation of inflammatory genes
- activating the secretion of anti-inflammatory proteins
- stabilising cell membranes
- decreasing the influx of inflammatory cells
Availability
Schering-Plough markets the medication under the following brand names; Elocon (Elocom, Elomet, Elosalic) as a cream or ointment for skin conditions, Nasonex as a nasal spray for upper respiratory conditions such as nasal sinus inflammation, Asmanex Twisthaler as a dry powder inhaler (DPI) for lower respiratory conditions. Essex pharma markets the medication under the brand name Ecural and Progreś Laboratories markets it under mometAid.
It is also available as a veterinary drug in an otic (ears) form for treatment of otitis externa under the brand name Mometamax.[7]
References
- ^ Zia R Tayab, Tom C Fardon, Daniel K C Lee, Kay Haggart, Lesley C McFarlane, Brian J Lipworth, and Günther Hochhaus (2007). "Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate". Br J Clin Pharmacol. 64 (5): 698–705. doi:10.1111/j.1365-2125.2007.02919.x. PMC 2203259. PMID 17509041.
{{cite journal}}
: Unknown parameter|month=
ignored (help)CS1 maint: multiple names: authors list (link) - ^ Tan RA, Corren J (2008). "Mometasone furoate in the management of asthma: a review". Ther Clin Risk Manag. 4 (6): 1201–8. PMC 2643101. PMID 19337427.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Bousquet J (2009). "Mometasone furoate: an effective anti-inflammatory with a well-defined safety and tolerability profile in the treatment of asthma". Int. J. Clin. Pract. 63 (5): 806–19. doi:10.1111/j.1742-1241.2009.02003.x. PMID 19392928.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Khope S (2010). "Topical mometasone furoate for phimosis". Indian pediatr. 47 (3): 282. PMID 20371899.
{{cite journal}}
: Unknown parameter|month=
ignored (help) - ^ Publishers, Jones and Bartlett (2009-07-15). Nurse's Drug Handbook 2010. p. 677. ISBN 9780763779009.
- ^ Mani S. Kavuru (2007). "ch. 9 Anti-inflammatory agents". Diagnosis and Management of Asthma. ISBN 9781932610383.
- ^ "Mometamax". Intervet USA. Retrieved 19 June 2010.